Florzolotau

N/A

Report date: 2026/05/26 20:00:28
NME

Base Information

Drug NameFlorzolotau
Drug Alias NameFlorzolotau 18F (Aprinoia Therapeutics)[18F]PM-PBB3APN-160718F-PM-PBB318F-APN-1607 +[10] 
ClassificationSmall molecules > Heterocyclic drugsRadiation-emitting products > Radioactive diagnostic agentDiagnostic agent (In vivo) > Radionuclide Imaging agent +[5] 
Mechanisms of ActionMicrotubule-associated protein tau inhibitorsPositron-emission tomography enhancers
TargetsMicrotubule-associated protein tau
Therapy Area/IndicationsDiagnostic agentsCognitive DysfunctionCognition Disorders +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAprinoia Therapeutics Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesBiogen IncInvicro LlcAprinoia Therapeutics Ltd +[6] 
Inactive CompaniesN/A
Active IndicationsDiagnostic agentsCognitive DysfunctionCognition Disorders +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBank